Perspective Therapeutics has entered into a clinical collaboration with Bristol Myers Squibb to investigate the safety and tolerability of its alpha-particle therapy [(212)Pb]VMT01 and Bristol Myers Squibb’s drug, nivolumab, for the treatment of MC1R-positive metastatic melanoma. As part of the…